Monthly Healthcare Review
March 2015
IPOs
The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.
Company Name
Last Financing
Date
HQ Location
Cerenis Therapeutics
(CEREN)
05-Mar-2015
Labege,
France
Redx Pharma (REDX)
26-Mar-2015
SteadyMed (STDY)
20-Mar-2015
Liverpool,
United
Kingdom
San Ramon,
CA
Description
Last
Financing
Size ($
millions)
Lead Manager(s)
Developer of high density lipoprotein (HDL) compounds for the treatment of
cardiovascular and metabolic diseases. The company’s products include Cerenis delta
compounds which reverse atherosclerotic disease by enhancing natural cardioprotective
mechanism in humans.
Developer of drugs for treating increasingly drug-resistant conditions, like influenza,
hepatitis C and HIV.
57.87
CM-CIC Securities
22.49
Shore Capital
Developer of medical devices for delivering injectable therapeutic drugs. The company’s
products are pre-filled drug-infusion patches that will be sold in conjunction with a
series of pharma and device companies.
39.95
Wells Fargo
Securities, RBC
Capital Markets
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
1
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
Adient Medical
Last Financing
Date
HQ Location
Round
9-Mar-15
Pearland, TX
Seed
Advanced Catheter
Therapies
17-Mar-2015
Aeglea BioTherapeutics
Holdings
23-Mar-2015
Alize Pharma
17-Mar-2015
Allergen Research
APR Applied Pharma
Research
Aura Biosciences
Auxogyn
12-Mar-15
25-Mar-2015
5-Mar-15
18-Mar-2015
Description
Last
Financing
Size ($
millions)
Lead Investor(s)
Developer of absorbable medical devices that vanish without
Undisclosed TMCx Accelerator
intervention after use. The company provides vascular filter for the
prevention of pulmonary embolism.
Chattanooga,
B
Developer of medical device and catheter technologies for the
4.50
ACT I Investments,
TN
treatment of vascular diseases and restenosis. The company focuses on
Chattanooga
moving the patented Occlusion Perfusion Catheter (OPC), an
Renaissance Fund,
intravascular agent delivery device, to sale or out-licensing.
Maclellan
Foundation
Austin, TX
B
Provider of drugs for the treatment of cancer. The company engages in
44.00
Lilly
Ventures,
clinical development of engineered human enzymes and developing
Novartis Venture
therapeutic enzymes for oncology. Its lead drug candidate AEB1102 is
Fund
being developed as an enzyme replacement therapy in patients with the
inborn errorofmetabolism
hyperargininemia
that isand
caused
by Arginase
Ecully, France
Later
Developer
biopharmaceutical
drugs, proteins
peptides.
The I
1.95
Sofimac Partners,
company develops therapeutic products for the treatment of diabetes,
Octalfa, Sham
cancer and metabolic diseases.
Innovation Santé
San Mateo, CA
B
Developer of immunotherapy for food allergies. The company
80.00
Foresite Capital
develops treatments to protect children with food allergies from the
consequences of accidental exposure.
Balerna,
PE Growth Developer of healthcare products. The company engages in the
Undisclosed
HBM Partners
Switzerland
development of oral and topical formulations, OTC pharmaceuticals,
nutraceuticals, dermocosmetics and medical devices. It also offers
consumer healthcare products for acute pain, cough & cold, insect
repellent, intimate care, legs healthcare, pediatric, pregnancy and
proctology.
Cambridge, MA
B
Developer of nanotechnology drug delivery systems for the treatment
21.02
Advent Life
of cancer. The company has developed a platform based on viral
Sciences
nanoparticles for the treatment of cancer.
Menlo Park, CA
B
Developer of a medical technology for advancing women’s
34.32
Undisclosed
reproductive health through scientific and clinical knowledge of early
human developmental biology. The company provides quantitative
information regarding embryo development to assist IVF clinicians in
optimizing the treatment path for their patients.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
2
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Last
Financing
Size ($
millions)
Lead Investor(s)
17.98
Undisclosed
Last Financing
Date
HQ Location
Round
Balance Therapeutics
18-Mar-2015
San Bruno, CA
B
Beta-O2 Technologies
30-Mar-2015
Rosh-Haayin,
Israel
Later
BioWink
18-Mar-2015
Berlin, Germany
Early
Developer of a fertility tracking application. The company enables users
to track their monthly cycle by entering data on various segments.
BrainCheck
9-Mar-15
Houston, TX
Seed
Brainstage
26-Mar-2015
Carnegie, PA
A
Cadence Biomedical
24-Mar-2015
Seattle, WA
Later
Cardiac Dimensions
11-Mar-15
Kirkland, WA
Tenth
Caribou Biosciences
24-Mar-2015
Berkeley, CA
A
Catabasis
Pharmaceuticals
17-Mar-2015
Cambridge, MA
B
3-Mar-15
Redmond, WA
Fifth
Developer of a brain diagnosis device. The company develops a device Undisclosed TMCx Accelerator
that helps in measurement of brain function designed to aid in the
diagnosis of traumatic brain injury.
Provider of process and cost improvements to the pharmacopeia and
2.20
Undisclosed
healthcare industries. The company is focused to provide innovative
and advanced technologies for gene expression and cell diagnostics,
toxicity analysis, personalized genomic medicine, drug discovery and
development
biomedical
Developer
of and
medical
devices.bioinformatics.
The company offers the Kickstart
0.96
Undisclosed
Walking System, a neurorehabilitation system to retrain walking
following stroke, incomplete spinal cord injury, and many other
neurological conditions.
Manufacturer
of devices for the treatment of heart failure and related
43.70
Life Sciences
conditions. The company develops minimally invasive implantable
Partners, Aperture
products to treat mitral valve regurgitation associated with congestive
Venture Partners,
heart failure.
also provides technology
CARILLON
Contour
System,
Arboretum
Developer
ofItCRISPR-Cas9
forMitral
precision
cell engineering.
11.55
Fidelity
Biosciences
The company offers technology-based services for cellular engineering
and analysis based on the CRISPR-Cas9 technology platform.
Developer of drugs to treat inflammatory condition and metabolic
12.41
Undisclosed
diseases. The company's technology enables the discovery and
development of small molecules that simultaneously target pathways in
the inflammatory
Developer
of toolsresponse.
for the treatment of ischemic stroke and other
11.38
Undisclosed
vascular disorders. The company develops treatment for acute ischemic
stroke using a combination therapy, known as sonothrombolyis.
Company Name
Cerevast Therapeutics
Description
Developer of therapeutics for Down's Syndrome and Alzheimer’s
disease. The company provides therapeutics to address conditions of
intellectual disability.
Provider of a proprietary implantable bioartificial pancreas. The
company provides a proprietary implantable bioreactor to be used as a
treatment and cure for type 1 diabetes.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Undisclosed Sherpa Innoventures
2.00
Brigitte Mohn,
French Groupe
Arnault, DR. KADE
3
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
Last Financing
Date
HQ Location
Round
Description
Last
Financing
Size ($
millions)
Lead Investor(s)
Undisclosed
TMCx Accelerator
Clear Ear
9-Mar-15
San Francisco,
CA
Seed
Developer of medical devices for cleaning ears. The company offers
medical devices that soften and remove ear wax.
Collegium
Pharmaceutical
10-Mar-15
Canton, MA
Ninth
Convergent Dental
31-Mar-2015
Natick, MA
B1
Daktari Diagnostics
2-Mar-15
Cambridge, MA
D
19-Mar-2015
Plano, TX
Later
Developer of treatments for chronic pain. The company also develops
50.00
TPG Biotech
and commercializes products for skin and skin related illnesses and
disorders.
Developer of a computer-guided tooth preparation system. The
9.00
Long River
company is a dental equipment and technology company and developer
Ventures, George
of Solea, a computer-aided, CO2 laser system for both hard and soft
Gund Foundation
tissue indications.
Developer
of products that provide diagnostic information to clinicians
15.50
Eastern Capital
and patients. The company is developing CD4, a handheld instrument
Limited and Merck
that offers electrical reading and reports of test results.
Global Health
Fund
Developer of a dental diagnostic technology. The company develops
Undisclosed Innovation
Undisclosed
diagnostic technology that integrates LEDs, advanced optics and digital
electronics into devices to improve and advance the care of dental
patients.
12-Mar-15
Hillsboro, OR
C
24-Mar-2015
San Carlos, CA
A1
DentLight
DiabetOmics
Eiger
BioPharmaceuticals
Developer of applications and technology to improve the diagnosis and
monitoring of diabetes and its complications. The company's tests and
services include gestational diabetes profile and personalized wellness
profile withoflaboratory
tests toagainst
identify
problem
areas.
Developer
antiviral agents
novel
targets
in the treatment of
hepatitis. The company focuses on the development of treatments for
strains of hepatitis. The company's pipeline includes preclinical new
chemical entities (NCEs)that is shown to possess antiviral activity
against Hepatitis C, Hepatitis D, and a wide array of other viruses.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
5.00
Ventureast and KI
Varaprasad Reddy
14.46
Undisclosed
4
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Last Financing
Date
HQ Location
Round
12-Mar-15
Berkeley, CA
Third
Emergency Medicine
Scribe Systems
EndoChoice
31-Mar-2015
El Segundo, CA
A2
5-Mar-15
Alpharetta, GA
Seventh
Fitbit
27-Mar-2015
San Francisco,
CA
Later
Flower Orthopedics
23-Mar-2015
Horsham, PA
C
Gauss Surgical
9-Mar-15
Los Altos, CA
Seed
Genprex
4-Mar-15
Austin, TX
Second
18-Mar-2015
Boston, MA
A
Company Name
Eko Devices
Ginkgo Bioworks
Description
Last
Financing
Size ($
millions)
Lead Investor(s)
Developer of an application to record heart sound. The company
2.00
Founder.org
allows doctors to visualize the audio waveform, record and playback
heart sounds and export them through email or electronic health
records. It helps doctors diagnose heart defects by transforming the
stethoscope into a powerful tool that can share, annotate and analyze
heart sounds
Provider of staff scribing services to hospitals and physicians. The
1.05
Undisclosed
company is a professional scribe staffing and training service for
healthcare providers.
Its services
include
transcriptions(GI)
of medical
Developer
of technologies
focused
on gastrointestinal
endoscopy.
57.00
Deerfield
The company provides devices, diagnostics, infection control and
imaging for specialists treating of gastrointestinal diseases.
Developer of digital health and fitness devices. The company is the
17.82
Undisclosed
developer of a family of mobile devices enabling users to make fitness
goals and track their progress, sharing their achievements with an online
community of users. The products include wireless trackers, a WI-Fipowered scale and a suite of mobile-application tools.
Developer and manufacturer of implants for orthopedic surgery
4.50
Undisclosed
products. The company develops pre-sterilized, bone-fixation and
implant products for orthopedic surgery.
Developer of a mobile computer vision platform to monitor surgical
Undisclosed TMCx Accelerator
blood loss in real time. The company is developing mobile applications,
cloud based computing and artificial intelligence to provide information
to assist the clinician in intraoperative fluid management and blood
transfusion.
Developer of clinical-stage bio-pharmaceutical products for cancer
0.16
Undisclosed
therapy. The company's leading product is Oncoprex and is a pankinase inhibitor that works to induce apoptosis in cancer cells and
control cell
inflammatory
pathways
to treat cancer
at the
Provider
of signaling
biologicaland
engineering
services.
The company
provides
9.00
Felicis Ventures, OS
biology technologies to design, build and test new organisms across a
Fund, Data
range of industries from fuels to pharmaceutical production.
Collective, iGlobe
Partners, Vast
Ventures
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
5
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Last
Financing
Size ($
millions)
Last Financing
Date
HQ Location
Round
Description
Glooko
17-Mar-2015
Palo Alto, CA
B
16.50
Medtronic, Canaan
Partners
GrayBug
5-Mar-15
Baltimore, MD
Fouth
Creator of diabetes-management application. The company provides an
HIPPAA-compliant diabetes management system enabling users to
download data from their glucose meters into their mobile device,
creating intelligence that can be shared and notated. Information
uploaded
patient
cansystems
be shared
providerThe
through the
Developerbyofthe
drug
delivery
to with
treat their
eye diseases.
company’s lead product is a polymer-drug biomolecular conjugate for
the treatment of neovascular diseases, including age-related macular
degeneration (AMD).
1.74
Hatteras Venture
Partners
Guardant Health
27-Mar-2015
Redwood City,
CA
C
55.90
Lightspeed Venture
Partners
Healint
31-Mar-2015
Singapoore,
Singapore
Seed
1.00
Wavemaker Pacific
Health Catalyst
17-Mar-2015
Salt Lake City,
UT
D
Provider of digital sequencing technology for blood tests. The company
develops a blood test for cancer that helps identify tumor genomic
alterations in real time.
Developer of a remote monitoring system for physicians. The
company's technology allows doctors and health stakeholders to take
advantage of mobile devices, sensors, machine learning and big data for
the management of chronic diseases.
Provider of healthcare data warehousing and analytics. The company
provides an analytics platform, data warehousing and process
improvement services for healthcare organizations and health systems.
70.00
Northwest Venture
Partners
Healthentic
19-Mar-2015
Seattle, WA
Later
Operator of a health care analytics company. The company offers data
analytic services that identifies health savings for employers.
3.75
HealthFinch
16-Mar-2015
Madison, WI
Later
Developer of a platform of applications to help doctors address
inefficiencies with their workflow that are not being addressed by the
current EMR solutions. The company's product allows physicians to
define custom protocols for medication refills allowing subsequent
access by their team.
2.40
Corvesta, Hawaii
Dental Service,
WDS Holdings,
WYSSTA
Jumpstart
Ventures
Company Name
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Lead Investor(s)
6
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
Last Financing
Date
HQ Location
Round
Description
Provider of a communication platform connecting doctors to patients.
The company provides a cloud-based platform that automates followup care and is designed to keep doctors, patients and caregivers
connected between visits, with actionable clinical information. The
company's peer-reviewed follow-up plans automate the routine aspects
of care while
tracking patient
progress
and monitoring
clinical
areas ofon
Provider
of healthcare
informatics
services.
The company
is focused
bringing evidence-based imaging analysis to the point of care.
13.15
Canvas Venture
Fund
4.50
Venture Investors
and 4490 Ventures
Provider of a healthcare application. The company offers a mobile
application which enables users to manage their medical records and
share them online with the doctors.
Developer of orthopedic medical devices. The company develops
products which includes a surgical tool that measures the position and
orientation of hip implants and provides a digital readout.
Developer of therapies to treat chronic venous insufficiency. The
company has developed a non-implantable, catheter based therapy, that
creates new valves out of the patient's native vein wall tissue.
1.30
Resolute Ventures
0.55
FedDev Ontario
5.92
Boston Scientific
Developer of surgical visualization and illumination technology for
applications in minimally invasive surgeries. The company offers
BriteField Port System that provides illumination and visualization
during minimally invasive procedures; and BriteField McCulloch
retractor, which allows physicians to achieve visualization during
surgery while
traditional techniques.
Operator
of a using
healthcare-information
services company. The company
provides a platform and device for long-term continuous cardiac
monitoring, to enable diagnosis earlier in the clinical pathway. The
company'sofwearable
products can
monitor
heart
rhythms
forNASA
up to 14
Provider
balance diagnostics
devices.
The
company
uses
technology
to
develop
a
scale
that
can
track
balance
and
is
designed
to
Developer of chronic disease therapeutics. The company is focused on
the discovery and development of molecules that modulate key
regulatory networks associated with chronic disease.
22.89
Wellington
Management
Company
27.34
Novo A/S
Undisclosed
5.50
TMCx Accelerator
Polaris Partners
HealthLoop
11-Mar-15
Mountain View,
CA
A
HealthMyne
10-Mar-15
Madison, WI
A
26-Mar-2015
Tel-Aviv, Israel
Early
5-Mar-15
Waterloo,
Canada
Third
19-Mar-2015
Mountain View,
CA
A
Invuity
9-Mar-15
San Francisco,
CA
Sixth
iRhythm Technologies
12-Mar-15
San Francisco,
CA
E
iShoe
KinDex
Pharmaceuticals
9-Mar-15
6-Mar-15
Houston, TX
Seattle, WA
Seed
A
Hello Doctor (Mobile
Application)
Intellijoint Surgical
InterVene
Last
Financing
Size ($
millions)
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Lead Investor(s)
7
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
Last Financing
Date
HQ Location
Round
Description
4-Mar-15
Aachen,
Germany
Second
26-Mar-2015
Oakland, CA
B
Lucigen
13-Mar-15
Middleton, WI
Angel
Provider of software products for image processing in biology and
medicine. The company provides an automatic detection and analysis
software tool to find number of collembols after flotation along with
Microbiology, an automatic detection and analysis tool for the detection
of colonies and colony counters.
Provider of cloud-based information feedback technology to save
energy and water in buildings. The company pioneered behavioral
efficiency and occupant engagement technology in commercial
buildings and the first vendor-neutral “operating system” for
commercial buildings with BuildingOS. The cloud-based software
creates a central information hub for building system, meter, and device
data while reducing
integration
costs.
Developer
of life science
research
products and technologies for
genetic cloning. The company develops technologies for advancements
in DNA cloning, sequencing, amplification, and protein expression.
Luneau Technology
5-Mar-15
Madison Vaccines
10-Mar-15
Medical Adhesive
Revolution
9-Mar-15
Mersana Therapeutics
2-Mar-15
LemnaTec
Lucid Design Group
Last
Financing
Size ($
millions)
Lead Investor(s)
5.60
Anterra Capital
14.12
Formation 8
2.23
Undisclosed
Pont de l’Arche, PE Growth Developer of ophthalmic diagnostic equipment. The company
Undisclosed
MML Capital
France
manufactures and distributes equipment from the visual diagnosis to
Partners, BNP
the manufacture of optical glass, used by ophthalmologists and
Paribas, Amundi and
opticians.
Credit Agricole
Madison, WI
A
Developer of DNA-vaccine products for the treatment of prostate
11.00
Venture Investors
cancer. The company is developing treatments designed to stimulate a
prostate cancer patient's immune system to destroy residual tumor cells
before they develop into overt bone metastases and to delay the need
for castration therapies.
Aachen,
Seed
Manufacturer
of medicinal adhesives. The company develops and
Undisclosed TMCx Accelerator
Germany
commercializes biodegradable surgical adhesive that can be used on the
skin and inside the human body to close wounds.
Cambridge, MA
B1
Developer of biodegradable and bio inert material for drug protection.
35.00
New Enterprise
The company's products conjugate for the treatment of multiple tumor
Associates
types and various preclinical oncology compounds.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
8
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
Last Financing
Date
HQ Location
Round
MHB Labs
18-Mar-2015
Chestnut Hill,
MA
Seed
Microscopy Innovations
19-Mar-2015
Marshfield, WI
Later
MindMaze
4-Mar-15
Ecublens,
Switzerland
Angel
Minimally Invasive
Devices
6-Mar-15
Columbus, OH
C
Modernizing Medicine
20-Mar-2015
Boca Raton, FL
D
MSI Methylation
Sciences
MuscleSound
23-Mar-2015
Burnaby, Canada
Later
11-Mar-15
Denver, CO
Seed
MySugr
11-Mar-15
Vienna, Austria
Seed
NanoLinea
9-Mar-15
Houston, TX
Seed
Description
Last
Financing
Size ($
millions)
Lead Investor(s)
Developer of medical products for management of erectile dysfunction.
1.10
Romulus Capital
The company develops pharmaceutical products for the management
of erectile dysfunction and anorgasmia.
Developer of novel products for microscopy laboratories. The
0.75
Undisclosed
company offers tools for the life science market lowering total
processing costs, improving turn-around time, and reducing error rates,
chemical usage and disposals.
Developer of a virtual reality (VR), augmented reality and motion
8.50
Undisclosed
capture game system, MindLeap. The company develops a product that
combines immersive virtual reality, motion capture and
neurophysiological recording technologies to build novel interfaces for
neurorehabilitation,
game
training andvision
threesystem.
dimensional
imaging in real
Developer
of FloShield
laparoscopic
The company
11.70
Canaan Partners,
develops a device that prevents loss of vision during laparoscopic
Charter Life
surgery due to obscuration of the optics.
Sciences
Developer of a cloud-based specialty-specific electronic medical record
20.00
Summit Partners,
system. The company's Electronic Medical Assistant product is used
Pentland Group
and built by practicing physicians to gather healthcare information and
improve outcomes It also provide additional facilities like specialtyspecific billing,
inventory management
purchasing
services.
Operator
of a biotechnology
company. and
Thegroup
company
develops
and
0.02
Undisclosed
markets a prescription drug used as a dietary supplement.
Developer of a technology to measure muscle glycogen. The company
4.30
Undisclosed
develops software, technology and methodology for measurement of
muscle glycogen levels and generates muscle-specific data reflective of
current muscle glycogen levels.
Developer of a diabetes monitoring application for smartphones. The
4.80
XLHealth, Roche
company offers an application that uses optical character recognition
Ventures, and iSeed
(OCR) software to use the smartphone’s camera to read the glucose
Ventures
reading number off the display screen of a connected blood glucose
meter and save it to the application.
Provider of therapeutic implant treatment for cardiac ventricular
Undisclosed TMCx Accelerator
arrhythmia. The company creates medical devices based on carbon
nanotube fiber technology.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
9
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Last Financing
Date
HQ Location
Round
Neurovance
24-Mar-2015
Cambridge, MA
A1
NGM
Biopharmaceuticals
26-Mar-2015
South San
Francisco, CA
D
Nightingale App
24-Mar-2015
Boston, MA
Seed
Nimbus Therapeutics
18-Mar-2015
Cambridge, MA
Ninox Medical
29-Mar-2015
Novan
NuScriptRX
Company Name
Description
Developer of a norepinephrine and dopamine-preferring reuptake
inhibitor for attention deficit hyperactivity disorder. The company
develops EB-1020 for adult attention deficit hyperactivity disorder
(ADHD) and a pipeline of research compounds for other CNS
disorders.
Developer of transformational biologics for the treatment of diabetes,
obesity and other cardio-metabolic diseases. The company develops
biotherapeutics to identify and validate novel targets that impact the
underlying etiology of metabolic diseases.
Last
Financing
Size ($
millions)
Lead Investor(s)
20.00
Novartis Venture
Fund
257.50
Merck
Provider of a mobile application to manage prescriptions. The company
offers a mobile application for patients and their caregivers that learns
the patient's schedule and reminds them to take their prescriptions.
0.66
Maverick Capital,
Stanford-StartX
fund, Y Combinator,
Keith Rabois and
Jaan Tallinn
B
Developer of biopharmaceutical products. The company is developing
biopharmaceutical products to diffuse large B-cell lymphoma, an
aggressive blood cancer, inflammatory disorders and metabolic disease.
43.00
Pfizer Venture
Investments,
Lightstone Ventures
Rishon LeZion,
Israel
Early
10.00
Xenia Venture
Capital
27-Mar-2015
Durham, NC
Later
50.00
Malin Corporation
18-Mar-2015
Nashville, TN
D1
Developer of a device for treating obstructive sleep apnea. The
company's device is designed to be effective, comfortable to use and
without the side effects.
Developer of therapeutic agents. The company develops products that
tap the anti-bacterial properties of nitric oxide by encapsulating the
compound in nano-particles that deliver therapeutic agents to desired
body location.
Provider of institutional pharmacy services. The company offers
medication dispensing model which has an utomated robotic system for
dispensing pharmaceuticals on a short cycle basis, providing
medications in specialized unit dose patient packaging.
3.85
Undisclosed
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
10
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Last Financing
Date
HQ Location
Round
12-Mar-15
Louisville, KY
Second
ODOS Industries
18-Mar-2015
Mansfield
Center, CT
Angel
OrthoSensor
23-Mar-2015
Dania Beach, FL
C
Ovid Therapeutics
Oxitone Medical
16-Mar-2015
9-Mar-15
New York, NY
Kfar Saba, Israel
Angel
Seed
Patient Route Systems
26-Mar-2015
Newton, MA
A
Pear Therapeutics
19-Mar-2015
Boston, MA
Early
Perceptimed
25-Mar-2015
Mountain View,
CA
A2
Company Name
NX Pharmagen
Description
Last
Financing
Size ($
millions)
Lead Investor(s)
Developer of blood-based molecular diagnostic testing products for
1.81
XLerate Health
cancer, prenatal care and various other conditions. The company
provides NeXosome, a prenatal and oncology diagnostics proteomics
platform that permits analysis of protein biomarkers shed specifically
from placental or tumor cells within protected exosomes (or
microvesicles) and harvested from blood samples.
Developer of electronic medical records system. The company's
0.28
Undisclosed
technology helps to maintain documenting patient encounters and
managing clinical information.
19.00
Bridger Healthcare
Developer of orthopedic implants and sensor-assisted surgery systems.
Ltd, Tullis Growth
The company’s sensor platform helps in external and implanted sensors
Fund
which can detect and monitor various functions in the musculoskeletal
system.
Developer of drugs for orphan diseases of the brain.
5.06
Undisclosed
Developer of wrist worn health monitoring system without fingertip
Undisclosed GEFEN Biomed
probe. The company's product enables continuous monitoring
Investments,
anywhere, anytime and alerting in emergency situations.
StartUp Health, and
TMCx Accelerator
Provider of a healthcare operations platform. The company offers an
7.00
Black Granite
online platform that enables doctors to schedule their surgeries,
Capital, Pierpoint
collaborate with patients and optimize resource utilization in hospitals.
Capital
Developer of digital health interventions to enhance the efficacy of
Undisclosed
pharmaceutical preparations. The company provides an online platform
designed for patients to access while they are taking their prescriptions.
The platform provides patients with information about their
prescription,
with patient
feedback to physicians,
fine tune the
Developer
ofalong
an advanced
pill identification
system. Thetocompany
5.36
provides IdentRx, a small device that determines the medication and
dosage of individual pills in real-time, checks each pill in a medication
pass against the doctor’s prescription. It also offers products for
prescription drug verification, pharmacy remote verification and will-
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
5AM Ventures
Undisclosed
11
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
PhaseBio
Pharmaceuticals
Pherecydes Pharma
PhoreMost
Portsmouth Regional
Ambulatory Surgery
Center
Provista Diagnostics
Pulmokine
Last Financing
Date
HQ Location
Round
Description
12-Mar-15
Malvern, PA
C
18-Mar-2015
Romainville,
France
Early
11-Mar-15
Cambridge,
United Kingdom
Seed
24-Mar-2015
Portsmouth, NH
Angel
16-Mar-2015
New York, NY
Later
4-Mar-15
Rensselaer, NY
First
Developer of biopharmaceuticals for metabolic and specialty
cardiopulmonary disorders. The company has developed once-weekly
insulin for type 2 diabetes and once-weekly Vasoactive Intestinal
Peptide for heart failure and cardiomyopahty in Duchenne and Becker
muscular dystrophy.
Developer of new products against emerging bacteria, combining
surveillance, detection and therapeutic tools based on phage
technology. The company develop new tools to rapidly detect and treat
people and their environment against a large range of biothreat agents,
including multi-resistant, emergent or previously uncharacterized
bacteria.
Developer of targeted drug therapies. The company is focused on
discovering drug therapies for disease targets intractable to current drugdiscovery technology. The company is the developer of a live-cell
phenotypic assay system that can rapidly identify unexpected, or
“cryptic” druggable sites in specific disease-driving targets and
pathways
be center.
readily The
seencompany
using conventional
non-cellsurgical
based
Operator that
of a can’t
surgery
offers ambulatory
healthcare services in the areas of orthopedic, ophthalmology, ears,
Provider
of oncology-based
nose, throat,
gynecology anddiagnostic
podiatry. tests and clinical laboratory
services to the pharmaceutical and biotechnology industries. The
company offers blood-based diagnostic tests for early oncology-related
disease state recognition and detection purposes. Its dtectDx-Breast
detects biomarkers using a blood sample which, when used in
Developer of new therapies for lung conditions like pulmonary arterial
hypertension (PAH) and related disorders. The company offers their
proprietary discoveries and solutions to other companies in their field,
and iss also developing a novel class of kinase inhibitors through insilico modeling and in-vitro screening.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Last
Financing
Size ($
millions)
Lead Investor(s)
40.00
AstraZeneca
2.82
ACE Management
Equity Partners
3.80
Jonathan Milner,
Sunil Shah, Prashant
Shah and Amadeus
Capital Partners
0.64
Undisclosed
3.87
Undisclosed
1.00
Broadview Ventures
12
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Last
Financing
Size ($
millions)
Last Financing
Date
HQ Location
Round
Description
10-Mar-15
Hayward, CA
B
Developer of solid-state ultraviolet (SSUV) LED technology. The
company provides patent-protected UV LED technology and materials,
with application for UV disinfection of water and air, and for UV
medical treatment devices.
9.30
RightClinic
19-Mar-2015
London, United
Kingdom
Early
0.37
Rigontec
24-Mar-2015
Bonn, Germany
A
Developer of an online booking platform for health and beauty clinics.
The company offers an online platform using which its users can book
appointments for laser eye surgery, cosmetic surgery, dental clinics,
browse deals and offers, check ratings and reviews of the people and
ask their queries in a forum.
Operator of a biotechnology company. The company develops
proprietary retinoic acid inducible gene I (RIG-I) activators for the
treatment of cancer.
Secure EDI
27-Mar-2015
Charlotte, NC
Later
Semma Therapeutics
24-Mar-2015
Cambridge, MA
A
Silicone Arts
Laboratories
24-Mar-2015
Memphis, TN
A
9-Mar-15
La Jolla, CA
Seed
Company Name
Rayvio
Skylit
Provider of software that interfaces among healthcare and dental
providers and payers. The company develops web-based services that
increases efficiency and helps to reduce costs through real-time
adjudication of claims, electronic funds transfers, on-line reconciliation
and data mining and informatics.
Developer of transformative therapies for type 1 diabetes patients. The
company offers a device to provide replacement for the missing beta
cells in a diabetic
immunosuppression.
Manufacturer
of apatient
topicalwithout
filler called
Dermaflage. The company uses
silicone to simulate skin and instantly conceal recessed imperfections.
Developer of a phototherapy device. The company develops a
phototherapy device that helps in the treatment of patients with
psoriasis, vitiligo and eczema diseases.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Lead Investor(s)
Applied Ventures,
Augment Ventures,
New Ground
Ventures, Tolero
Ventures, DCM
Ventures
Forward
Partners
15.44
Wellington Partners,
Boehringer
Ingelheim Venture
Partners
8.81
Undisclosed
44.00
MPM Capital
1.50
Innova Memphis
Undisclosed
EvoNexus,
Founder.org, and
TMCx Accelerator
13
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
Last Financing
Date
HQ Location
Round
Sonormed
31-Mar-2015
Hamburg,
Germany
A
StratoScientific
20-Mar-2015
Seattle, WA
Angel
Svelte Medical Systems
19-Mar-2015
New
Providence, NJ
Later
Swallow Solutions
13-Mar-15
Madison, WI
A
TeleSkin
10-Mar-15
Belgrade, Serbia
Second
31-Mar-2015
Montreal,
Canada
D
Thrasos Therapeutics
Description
Developer of a therapy for treatment of tinnitus. The company
develops an audiology technology that offers neuroacoustic treatment
for ringing in the ears.
Developer of medical devices. The company develops devices that are
used in medical practices. The portfolio of products includes the
StethIO, a smartphone stethoscope for visualizing and hearing heart
sounds and the LesionSizer, a device to decrease stents in angioplasty
due to inaccurate lesion length measurement.
Developer of balloon expandable stents. The company designs and
develops non thrombogenic and non inflammatory drug eluting stents
for the treatment of atherosclerosis.
Operator of life sciences company with a dysphagia treatment platform.
The company focuses on two areas related to dysphagia – therapeutic
devices for diagnosing and treating swallowing disorders and nutritional
food products tailored to the patient’s diagnosed level of swallowing
difficulty.
Provider of a clinical skin cancer analysis platform. The company offers
hardware and software services with a clinical multi-spectral
dermascope for the medical practioner to conduct a detailed
dermascopic analysis of moles and other skin lesions.
Developer of therapies for the prevention and treatment of severe
organ failure with a principal focus on kidney disease. The company's
lead therapeutic program, THR-184, is focused on the prevention and
treatment of acute kidney injury (AKI). It also has a preclinical
development program for treating chronic kidney disease (CKD).
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Last
Financing
Size ($
millions)
Lead Investor(s)
Undisclosed
High-Tech
Gründerfonds,
Innovationsstarter
Fonds Hamburg,
Quotas Beteiligungs
and Heiko Hubertz
0.70
Undisclosed
38.00
CNF Investments
2.06
Venture
Management
0.94
SEED Capital
Denmark and
Accelerace
21.00
SR One, BDC
Capital
14
Monthly Healthcare Review
March 2015
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies
announced over the previous month.
Company Name
Last Financing
Date
HQ Location
Round
Description
Operator of a bio-pharmaceutical company. The company focuses on
the discovery and development of first-in-class therapeutics for kidney
diseases.
Developer and provider of medical devices. The company provides a
mobile-connected 12-lead ECG. The 12 leads role up into a package
and, combined with the app, are designed to allow doctors to take ECG
readings on the go — in home care settings, in transit between care
settings, or of
in an
global
health contexts.
Developer
immunotherapy
treatment for the treatment of brain
and kidney cancers. The company is focused on cancer cell vacination
and T-cell cancer treatment.
Operator of a biotechnology company. The company is a provider of
translational genomics services.
Operator of a medical device company that engages in developing,
manufacturing and marketing stents to treat chronic venous diseases.
The company offers Vici Venous Stent System that is used to treat
venous outflow obstruction in the lower extremities.
Tricida
4-Mar-15
South San
Francisco, CA
B
Triomi Medical
Innovations
9-Mar-15
Miami, FL
Seed
30-Mar-2015
Lenexa, KS
Later
UberSeq
10-Mar-15
Palo Alto, CA
Seed
Veniti Medical
10-Mar-15
St. Louis, MO
C
TVAX Biomedical
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Last
Financing
Size ($
millions)
Lead Investor(s)
30.00
OrbiMed
0.12
Sprint Accelerator
2.00
Undisclosed
0.38
Undisclosed
17.00
Baird Capital, Tekla
Healthcare, and
Tekla Life Science
Investors
15
Monthly Healthcare Review
March 2015
Mergers and Acquisitions
The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Acquirer
Target
HQ Location
3M
Ivera Medical
San Diego, CA
4d pharma
GT Biologics
Aberdeen, United
Kingdom
Amplifon
Dilworth Hearing
Auckland, New Zealand
Baxter International
SuppreMol
Munich, Germany
Becton Dickinson &
Company
Crisi Medical
Systems
San Diego, CA
Biosafe Group
Biosafe Brasil
Distribuidora
Brazil
CreatiVasc Medical
Greenville, SC
Marlin Equity
Partners
Austin, TX
Brookhaven Medical
e-MDs
Date
Target Description
Transaction
Value ($
millions)
13-Mar-2015 Developer and seller of disinfection products to reduce hospital acquired
Undisclosed
infections. The company specializes in the design, development, manufacturing,
marketing and selling of the Curos line of products including passive disinfection
port protectors that disinfect and then cover needleless valves to prevent
contamination between venous accesses.
30-Mar-2015 Developer of Biotherapeutics for the treatment of autoimmune diseases. The
1.2
company develops approved Biotherapeutic products with proven efficacy for
the treatment and management of debilitating paediatric inflammatory bowel
diseases and other autoimmune diseases.
19-Mar-2015 Provider of hearing products and services. The company provides hearing-aids
Undisclosed
and related products such as batteries, accessories, spare parts and services.
04-Mar-2015 Developer of therapeutics for the treatment of autoimmune diseases and allergic
225.00
diseases. The company is focused on development of soluble Fc-gamma
receptors (FcyRs), which are recombinant autologous therapeutic proteins with a
specific immunoregulatory potential.
02-Mar-2015 Developer of drug-delivery systems. The company's products are designed to
Undisclosed
improve clinical outcomes and lower healthcare costs by making the delivery of
intravenous injectable drugs safer and more accurate.
30-Mar-2015 Distributor of cell processing systems. The company is primarily engaged in
Undisclosed
distribution of regenerative medicine, stem cells banking and automated cell
processing systems for the medical industry.
10-Mar-2015 Developer of medical devices for the treatment of end stage renal diseases. The
company develops vascular technologies that addresses the problems of kidney
dialysis connectivity.
31-Mar-2015 Developer of integrated electronic health records and practice management
software. The company is an industry leader for usable, connected software that
enables physician productivity and a superior clinical experience.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Undisclosed
Undisclosed
16
Monthly Healthcare Review
March 2015
Mergers and Acquisitions
The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Acquirer
Target
HQ Location
InKaryo
Mountain View, CA
CUI International
Leicester, United
Kingdom
Healthstream
HealthLine Systems
San Bernardino, CA
Hinduja Global
Solutions Limited
Colibrium Partners
Roswell, GA
Impax Laboratories
Amedra
Pharmaceuticals
Horsham, PA
Impax Laboratories
CorePharma
Middlesex, NJ
Impax Laboratories
Lineage
Therapeutics
Horsham, PA
Intelligent Hospital
Systems
Amerisource
Bergen Technology
Group
Buffalo Grove, IL
Esperite
H&R Healthcare
Date
Target Description
19-Mar-2015 Provider of cytogenetic analysis services. The company's experimental protocol
and proprietary bioinformatics analysis cover the full genome evenly with
specific and accurate digital sequence output thus providing next generation
sequencing platforms, sequencing reagents, sequencing applications, genomic
diagnostics, and bioinformatics.
23-Mar-2015 Manufacturer of specialist medical support products. The company designs and
develops parastomal hernia support products and specialist stoma underwear.
17-Mar-2015 Provider of credentialing software, contact center software and quality
management software to hospitals and healthcare organizations. The company
also provides web-based credentialing software.
30-Mar-2015 Provider of software products to the healthcare industry. The company offers
CRM systems, management consulting, database software, health plan
automation and wellness automation platform software and services.
10-Mar-2015 Provider of prescription products in the United States. The company offers an
emergency injection of epinephrine used for the treatment of life-threatening
allergic reactions known as anaphylaxis.
10-Mar-2015 Developer and manufacturer of solid dose generic pharmaceuticals, including
prescription and over-the-counter products. The company focuses on solid oral
dosage forms, both modified and immediate release dosage forms and controlled
drug products.ofIt pharmaceutical
manufactures and
handlesThe
C-II,
C-III, C-IV
and C-V
10-Mar-2015 Manufacturer
products.
company
develops
and drugs, as
manufactures injections, capsules and tablets used for severe swelling, breathing
problems and loss of blood pressure.
09-Mar-2015 Provider of pharmacy and medical automation services. The business unit offers
pharmacies dispensing, multi-facility health systems, streamline medication
management processes and control costs.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Transaction
Value ($
millions)
40
Undisclosed
88
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Undisclosed
17
Monthly Healthcare Review
March 2015
Mergers and Acquisitions
The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Acquirer
Target
HQ Location
XO1
Cambridge, United
Kingdom
Kite Pharma
Kite Pharma EU
Haarlem, Netherlands
Meadowlark Optics
Cambridge
Research &
Instrumentation
(Product line)
Streamline
(Healthcare)
Frederick, CO
Janssen
Pharmaceuticals
Medovex
Medtronic
Sophono
Merry X-Ray
Corporation
Lupica Medical
Systems
NTC Pharma
Wise SGR
Paragon Partners
Medentech
Pharmalink
Prestium Pharma
Synartro
Zonalon
(MEDICATED
SKIN CREAM)
Date
Target Description
Developer of anticoagulant drugs to prevent heart attack and stroke without
19-Mar-2015 causing bleeding. The company develops ichorcumab drugs and operates
virtually by engaging contract research and development specialists in Europe
and the US, managed by a small team of experienced drug developers.
18-Mar-2015 Provider of gene therapy services. The company specializes in providing gene
therapy platforms for the treatment of cancer.
26-Mar-2015 Provider of multi-spectral diagnostic imaging services. The business division
designs and manufactures liquid crystal 1x128 and 1x640 spatial light modulator.
It is an electrically programmable device that modulate light in a fixed spatial
Developer
of medical intravenous transport system. The company provides the
(pixel) pattern.
Eden Prairie, MN
26-Mar-2015 Streamline IV (intravenous) Suspension System (ISS), a multipurpose transport
system that combines the advantages of both stand-alone and bed-mounted IV
poles in one system. The ISS pole is designed to attach and lock to any transport
Boulder, CO
26-Mar-2015 Developer of implantable bone conduction hearing devices. The company
provides hearing devices for individuals suffering from severe to profound
hearing loss and impairment.
North Royalton, OH
23-Mar-2015 Supplier of healthcare imaging equipment. The company provides x-ray
equipment and film-processor accessories to hospitals, orthopedics, imaging
centers, podiatrists, chiropractors and veterinarians.
Milan, Italy
20-Mar-2015 Operator of an international pharmaceutical company. The company is active in
the fields of niche generic pharmaceuticals and over-the-counter (OTC) drugs, as
well as medical devices and food supplements.
Wexford, Ireland
03-Mar-2015 Manufacturer of disinfection products. The company offers water purification
tablet to prevent cholera, typhoid, dysentery and other water borne diseases. It
also provides disinfectants, sterilizers and other related products for hospital,
livestock and machinery markets.
Uppsala, Sweden
18-Mar-2015 Developer of anti-inflammatory drug using the drug delivery technology. The
company is involved in developing a pipeline of repositioned drug candidates for
important medical needs.
Hitchin, United Kingdom 18-Mar-2015 Rights to a pharmaceutical skin cream. The skin cream, Zonalon (doxepin
hydrochloride) is used to treat itching from a range of skin conditions, including
atopic cermatitis, eczema and neurodermatitis.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Transaction
Value ($
millions)
Undisclosed
20
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Undisclosed
18
Monthly Healthcare Review
March 2015
Mergers and Acquisitions
The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Acquirer
Target
HQ Location
HalioDx
Marseille, France
RoundTable
Healthcare Partners
Tower Holdings
Horsham, PA
Simplify Medical
M.H. Carnegie &
Co.
Mountain View, CA
Ranbaxy
Laboratories (7666)
Gurgaon, India
Indus Meditech
Delhi, India
H-Net
Zürich, Switzerland
Whole You
Respire Medical
Holdings
Brooklyn, NY
WS Rothband
Seneca Partners
Rossendale, United
Kingdom
Qiagen Marseille
Sun Pharmaceuticals
Sunrise Asian
Swisscom
Date
Target Description
23-Mar-2015 Provider of diagnostic services. The company develops, produces and markets a
portfolio of diagnostic products focused on immuno-oncology. It also offers
new treatments in the field of immuno-oncology.
10-Mar-2015 Developer of complex branded and generic pharmaceutical products. The
Companies specialize in high value generic formulations including extendedrelease, delayed-release and DEA controlled substances
23-Mar-2015 Developer of cervical artificial disc that optimizes MRI imaging. The company
operates several outpatient physical therapy clinics throughout Las Vegas Valley.
Its simplify disc incorporates advanced materials to provide a metal free service,
optimum imaging capability and kinematics.
25-Mar-2015 Owner and operator of a multinational pharmaceutical company. The company
manufactures and markets generic, branded generic, value-added and over-thecounter products, anti-retrovirals, active pharmaceutical ingredients and
intermediates.
25-Mar-2015 Seller and distributor of medicines to the pharmaceutical industry. The company
is engaged in the clinical research, development and distribution of medicines to
healthcare professionals and patients.
23-Mar-2015 Developer of database management software for the healthcare sector. The
company provides digital data exchange and electronic invoicing services to
hospitals, cantons, radiologists, physicians, laboratories and home care.
18-Mar-2015 Manufacturer of oral appliances. The company offers functional and aesthetic
devices to help treat patients who snore, have Obstructive Sleep Apnea and
Temporomandibular Joint Disorder symptoms.
24-Mar-2015 Manufacturer of equipment for radiology departments. The company
manufacturers a range of lead-shielding products and equipment for radiology
darkrooms and processing areas. Its products include lead aprons. mitts &
protective curtains, as well as patient-positioning sets, imaging chairs and
darkroom furniture.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
Transaction
Value ($
millions)
Undisclosed
700.00
Undisclosed
4,000
Undisclosed
Undisclosed
Undisclosed
Undisclosed
19
Monthly Healthcare Review
March 2015
Mergers and Acquisitions
The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Acquirer
ZeOmega
Target
HQ Location
HealthUnity
Bellevue, WA
Date
Target Description
Transaction
Value ($
millions)
23-Mar-2015 Provider of software products and services for health information exchange. The Undisclosed
company provides a health information network that enables integrated delivery
networks to create a longitudinal view of the patient's clinical information.
Compiled By: Randall Hoyle
Sources: PitchBook, Wall Street Journal, SEC Filings, Company Press Releases, FinSMEs.com, fiercebiotech.com, PE HUB, and biospace.com
20